Oncolytics Biotech Inc

Financials

Total assets ————— Total liabilities 6.73 M6.73 M6.73 M6.73 M6.73 M Total equity ————— Total liabilities & shareholders' equities 6.73 M6.73 M6.73 M6.73 M6.73 M Total debt ————— Net debt —————

Oncolytics Biotech Inc. is a Canadian company headquartered in Calgary, Alberta, that is developing an intravenously delivered immuno-oncolytic virus called pelareorep for the treatment of solid tumors and hematological malignancies. Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus that induces selective tumor lysis and promotes an inflamed tumor phenotype through innate and adaptive immune responses.

ONCY

Financials

Oncolytics Biotech Inc

Haberler

Oncolytics GOBLET çalışmasını sonlandırıyor, ABD onayına odaklanıyor

Oncolytics to wind down GOBLET study, focus on U.S. registration

Oncolytics Biotech hisseleri FDA’nın Hızlı İzleme Statüsü vermesiyle yükseldi

Oncolytics Biotech stock soars after FDA grants Fast Track Designation

Pelareorep-atezolizumab shows promising results in anal cancer

Oncolytics Biotech plans to shift incorporation from Canada to Nevada

Oncolytics Biotech, pelareorep korumasını uzatmak için patent başvurusu yaptı

Oncolytics Biotech files patent application to extend pelareorep protection

Oncolytics Biotech expands GI cancer advisory board with three experts

Oncolytics reports 33% response rate in hard-to-treat colorectal cancer

Oncolytics Biotech reschedules shareholder vote on U.S. domicile move

Oncolytics Biotech (ONCY) Loses 8.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner